Recent Quotes (30 days)

You have no recent quotes
chg | %

Oncolytics Biotech Inc.  

(Public, TSE:ONC)   Watch this stock  
Find more results for ONC
0.000 (0.00%)
Oct 25 - Close
TSE data delayed by 15 mins - Disclaimer
Currency in CAD
Range 0.31 - 0.32
52 week 0.30 - 0.75
Open 0.31
Vol / Avg. 317,888.00/71,867.00
Mkt cap 39.80M
P/E     -
Div/yield     -
EPS -0.11
Shares 120.49M
Beta 1.22
Inst. own     -
Nov 3, 2016
Q3 2016 Oncolytics Biotech Inc Earnings Release (Estimated) Add to calendar
Sep 13, 2016
Oncolytics Biotech Inc at Rodman & Renshaw Global Investment Conference
Aug 11, 2016
Oncolytics Biotech Inc at Canaccord Genuity Growth Conference
Aug 4, 2016
Q2 2016 Oncolytics Biotech Inc Earnings Release

Key stats and ratios

Q2 (Jun '16) 2015
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -46.64% -61.57%
Return on average equity -53.01% -71.30%
Employees 22 -
CDP Score - -


210-1167 Kensington Cres NW
+1-403-6707377 (Phone)
+1-403-2830858 (Fax)

Website links


Oncolytics Biotech Inc. is a development-stage company. The Company is focused on the development of REOLYSIN, its cancer therapeutic. The Company's clinical program is made up of a registration program that includes muscle-invasive bladder cancer and glioma cancer, over six randomized Phase II clinical trials and approximately six other investigative clinical trials. The Company focuses on the registration of REOLYSIN in approximately two indications, including the neoadjuvant treatment of muscle-invasive bladder cancer and the treatment of glioblastoma. The Company has conducted a single arm United States Phase II non-small cell lung cancer (NSCLC) trial and a single arm United States Phase II pancreatic cancer trial for REOLYSIN. The Company is also engaged in conducting a Phase Ib trial for REOLYSIN and chemotherapy in combination with pembrolizumab in its Checkpoint Inhibitor Program.

Officers and directors

Bradley G. Thompson Ph.D. Executive Chairman of the Board, President, Chief Executive Officer
Kirk J. Look Chief Financial Officer
Matthew C. Coffey Ph.D. Chief Operating Officer, Director
George M. Gill M.D. Senior Vice President - Regulatory Affairs & Chief Safety Officer
Alan J. Tuchman M.D. Chief Medical Officer, Senior Vice President - Medical and Clinical Affairs
Age: 68
Mary Ann Dillahunty J.D. Vice President - Intellectual Property
Angela Frances Holtham Director
Edwin Levy Ph.D. Director
J. Mark Lievonen Director
Linda M. O. Hohol Independent Director
Age: 63